Format

Send to

Choose Destination
Laryngoscope. 2011 Feb;121(2):313-9. doi: 10.1002/lary.21258. Epub 2011 Jan 13.

Long-term results of calcium hydroxylapatite for vocal fold augmentation.

Author information

1
Center for Voice and Swallowing, Department of Otolaryngology, Tufts Medical Center, Boston, Massachusetts, Pittsburgh, Pennsylvania, USA.

Abstract

OBJECTIVES/HYPOTHESIS:

Studies have shown excellent results for 12-month post-injection augmentation data for calcium hydroxylapatite (CaHA) for glottal incompetence; however, the longevity of the material past one year was unknown. Our objective was to report the long-term effectiveness of CaHA as a vocal fold injectable by assessing data from a cohort of patients who underwent injection for glottal insufficiency.

STUDY DESIGN:

Retrospective chart review.

METHODS:

Patients who underwent CaHA injection for glottal insufficiency of any etiology were considered for inclusion in the study. The change in Voice Handicap Index (VHI)-10 scores between preinjection scores and best postinjection scores as well as between the preinjection and the most recent VHI-10 scores were used as primary outcome measures to determine the persistence of benefit or the time to loss of benefit. Complications among the cohort were identified.

RESULTS:

Ninety patients who underwent 108 vocal fold injections with CaHA were evaluated for inclusion. Twenty patients with 22 injections met the criteria for inclusion. Fourteen of 22 (64%) subjects showed loss of benefit of the CaHA material. The average length of benefit was 18.6 months, with a range of 8 to 36 months. Three complications were identified among the original cohort of 108 injections.

CONCLUSIONS:

CaHA remains a safe and effective long-term vocal fold injectable with an average length of benefit of 18.6 months. Three complications were seen among 108 CaHA injections. CaHA is a long-term injectable with an excellent track record that does not appear to warrant concern for permanent or late complications.

PMID:
21271580
DOI:
10.1002/lary.21258
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center